Cite
Advances in the treatment of relapsing–remitting multiple sclerosis – critical appraisal of fingolimod
MLA
Gasperini C, et al. “Advances in the Treatment of Relapsing–remitting Multiple Sclerosis – Critical Appraisal of Fingolimod.” Therapeutics and Clinical Risk Management, vol. 2013, no. default, Mar. 2013, pp. 73–85. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.44bf4b0502124a9ea12abd3929f6a9a3&authtype=sso&custid=ns315887.
APA
Gasperini C, Ruggieri S, Mancinelli CR, & Pozzilli C. (2013). Advances in the treatment of relapsing–remitting multiple sclerosis – critical appraisal of fingolimod. Therapeutics and Clinical Risk Management, 2013(default), 73–85.
Chicago
Gasperini C, Ruggieri S, Mancinelli CR, and Pozzilli C. 2013. “Advances in the Treatment of Relapsing–remitting Multiple Sclerosis – Critical Appraisal of Fingolimod.” Therapeutics and Clinical Risk Management 2013 (default): 73–85. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.44bf4b0502124a9ea12abd3929f6a9a3&authtype=sso&custid=ns315887.